Cryo-Cell International, Inc. (CCEL) - Q3 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended August 31, 2024. Cryo-Cell International, Inc. operates in three segments: private cellular processing and cryogenic storage, manufacture of PrepaCyte CB units, and public cord blood banking. The company is headquartered in Oldsmar, Florida, and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Aug 31, 2024 | Nine Months Ended Aug 31, 2024 |
|---|---|---|
| Total Revenue | $8,066,715 | $23,961,761 |
| Net Income | $1,051,679 | $2,263,710 |
| Operating Income | $1,389,890 | $3,602,631 |
| Net Cash from Operating Activities | N/A | $3,853,917 |
| Cash and Cash Equivalents | $197,437 | $197,437 |
| Marketable Securities | $1,929,458 | $1,929,458 |
| Total Debt (Current + Long-Term) | $8,680,217 | $8,680,217 |
| Stockholders' Deficit | ($9,558,956) | ($9,558,956) |
Note: Debt includes a $2,222,728 line of credit and a term loan facility. Stockholders' deficit reflects accumulated losses and treasury stock.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 3% year-over-year for the three months ended August 31, 2024, driven by a 5% increase in recurring annual storage fees, partially offset by a 14% decrease in new domestic cord blood specimens processed.
- Profitability: Net income rose 54% to $1.05 million for the quarter, compared to $680,561 in the prior year period. This was aided by a significant gain on marketable securities ($522,458) and reduced interest expense.
- Public Banking Volatility: Public cord blood banking revenue surged to $120,609 in Q3 2024 from $4,383 in Q3 2023, attributed to demand volatility.
- Investment Impairment: The company recorded a $308,000 impairment charge on its investment in Tianhe stock during the nine-month period, compared to zero in the prior year.
- Debt Utilization: The line of credit balance increased from $1.22 million to $2.22 million, while the company repurchased $1.42 million of its own stock during the nine-month period.
Outlook, Risks, and Contingencies
- Duke University Arbitration: On October 4, 2024, the company filed a demand for arbitration against Duke University, alleging fraudulent inducement and breach of the Duke License Agreement. Cryo-Cell claims damages exceeding $100 million. This dispute has paused the planned opening of the Cryo-Cell Institute for Cellular Therapies and the proposed spinoff of the subsidiary Celle Corp.
- Liquidity: Management anticipates that cash, marketable securities, and operating cash flows will be sufficient to fund known needs for the next 12 months. However, future funding needs related to the Duke agreement remain unpredictable pending the arbitration outcome.
- Legal Proceedings: A class-action lawsuit regarding advertising claims (Lindsey Lehr v. Cryo-Cell) was stayed and compelled to arbitration in October 2023; the company believes the claims are without merit.
- Capital Expenditures: The company received a Certificate of Occupancy for its new 56,000 sq. ft. facility in Durham, North Carolina, in May 2024, intended for the "ExtraVault" third-party cold storage service.
Investor Verification Checklist
- Arbitration Status: Monitor the outcome of the Duke University arbitration, as a loss could impact the company's ability to commercialize licensed therapies and validate the $100M+ damage claim.
- Spinoff Viability: Verify if the Celle Corp. spinoff proceeds, as it is currently on hold pending the Duke dispute resolution.
- Debt Covenants: Review compliance with the Susser Bank credit agreement covenants (Leverage Ratio < 3.50:1; Debt Service Coverage Ratio > 1.25:1).
- Deferred Revenue: Assess the $55 million in deferred revenue, which represents future obligations and revenue recognition over long-term storage contracts.
- Stock Repurchases: Track the remaining capacity under the share repurchase plan (1,212,540 shares remaining as of August 31, 2024).